These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 793522)

  • 1. Toxoid of Clostridium botulinum type F: purification and immunogenicity studies.
    Hatheway CL
    Appl Environ Microbiol; 1976 Feb; 31(2):234-42. PubMed ID: 793522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Toxoids of botulinum toxin type G].
    Puig de Centorbi ON; Ciccarelli AS; Giménez DF
    Rev Argent Microbiol; 1980; 12(1):10-7. PubMed ID: 6755549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on immunity to toxins of Clostridium botulinum. VII. Purification and detoxification of trypsin-activated type E toxin.
    FIOCK MA; YARINSKY A; DUFF JT
    J Bacteriol; 1961 Jul; 82(1):66-71. PubMed ID: 13699727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and properties of Clostridium botulinum type F toxin.
    Yang KH; Sugiyama H
    Appl Microbiol; 1975 May; 29(5):598-603. PubMed ID: 807160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clostridium botulinum type B vaccine for prevention of shaker foal syndrome.
    Thomas RJ; Rosenthal DV; Rogers RJ
    Aust Vet J; 1988 Mar; 65(3):78-80. PubMed ID: 3041951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Clostridium botulinum type C antitoxin titers in mink and guinea pigs to protection against type C intoxication in mink.
    Kolbe DR; Coe Clough NE
    Anaerobe; 2008 Apr; 14(2):128-30. PubMed ID: 18032073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.
    Keller JE
    Clin Vaccine Immunol; 2008 Sep; 15(9):1374-9. PubMed ID: 18667637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of clostridium sordellii LT and HT toxoids against challenge with spores in guinea pigs.
    Amimoto K; Oishi E; Yasuhar H; Sasak O; Katayama S; Kitajima T; Izumida A; Hirahara T
    J Vet Med Sci; 2001 Aug; 63(8):879-83. PubMed ID: 11558543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component.
    Mahmut N; Inoue K; Fujinaga Y; Arimitsu H; Sakaguchi Y; Hughes L; Hirst R; Murphy T; Tsuji T; Watanabe T; Ohyama T; Karasawa T; Nakamura S; Yokota K; Oguma K
    J Med Microbiol; 2002 Oct; 51(10):813-820. PubMed ID: 12435059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of Clostridium septicum alpha-toxoid vaccine against challenge with spores in guinea pigs.
    Amimoto K; Ohgitani T; Sasaki O; Oishi E; Katayama S; Isogai M; Ota S
    J Vet Med Sci; 2002 Jan; 64(1):67-9. PubMed ID: 11853149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics study of immunological response to Clostridium botulinum toxin.
    Dezfulian M; Bitar RA; Bartlett JG
    J Clin Microbiol; 1987 Jul; 25(7):1336-7. PubMed ID: 3301895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preparation of purified shorbed botulinum toxoid type F. I. Comparative evaluation of different nutrient media for producing active type F botulinum toxin].
    Tsarapkin VP
    Zh Mikrobiol Epidemiol Immunobiol; 1971 Oct; 48(10):28-31. PubMed ID: 4941812
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of humoral neutralizing antibody response in rabbits, guinea pigs, and cattle vaccinated with epsilon and beta toxoids from Clostridium perfringens and C. botulinum types C and D toxoids.
    Silva ROS; Duarte MC; Oliveira Junior CA; de Assis RA; Lana AMQ; Lobato FCF
    Anaerobe; 2018 Dec; 54():19-22. PubMed ID: 30076896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antigenicity of Clostridium botulinum type C toxin administered per os.
    Jansen BC; Knoetze PC; Visser F
    Onderstepoort J Vet Res; 1970 Sep; 37(3):169-71. PubMed ID: 4949136
    [No Abstract]   [Full Text] [Related]  

  • 15. Botulinal toxin and toxoid as antigens.
    Heimach RC; Champion LA; Sugiyama H
    Proc Soc Exp Biol Med; 1970 Oct; 135(1):151-4. PubMed ID: 4920940
    [No Abstract]   [Full Text] [Related]  

  • 16. [Properties of C1. perfringens toxoids obtained from purified toxins].
    Dmitrieva LN; Shemanova GF; Vlasova EV; Akhundova KA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Apr; (4):110-4. PubMed ID: 868405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of purified sorbed botulinum toxoid type F. II. Activity of crude toxins and toxoids].
    Tsarapkin VP
    Zh Mikrobiol Epidemiol Immunobiol; 1971 Nov; 48(11):105-8. PubMed ID: 4944335
    [No Abstract]   [Full Text] [Related]  

  • 18. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenicity of Clostridium botulinum type-E formol toxoid.
    Kondo H; Kondo S; Murata R; Sakaguchi G
    Jpn J Med Sci Biol; 1969 Apr; 22(2):75-85. PubMed ID: 4899485
    [No Abstract]   [Full Text] [Related]  

  • 20. Clostridium botulinum subtype Ba.
    Giménez DF
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 May; 257(1):68-72. PubMed ID: 6380157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.